Abstract:Objective: T-cell exhaustion in hepatitis B virus (HBV) infection, which results from upregulation of programmed cell death-1 (PD-1), leads to persistent HBV infection and related disease progression. Therefore, agents targeting PD-1 may prove beneficial in the treatment of this condition. MicroRNA-138 (miR-138) possesses an anti-tumor ability in that it targets immune checkpoints, including PD-1. However, the function and underlying mechanisms of miR-138 in patients with HBV infection remains unclear. Methods: Specimens were collected from healthy volunteers (n = 43) and patients with chronic hepatitis B (CHB; n = 52), liver cirrhosis (LC; n = 26), and hepatocellular carcinoma (HCC; n = 31); carriers of HBV who were asymptomatic (n = 51); and patients with CHB receiving antivirus treatment (n = 11). These specimens were then used to study the expression and relationship among miR-138, PD-1, and HBV DNA viral load. To investigate the role of miR-138 in regulating PD-1 expression and determine the effect of miR-138 in regulating T-cell function, a luciferase assay and a transfection assay were each performed with primary CD3+ T cells. Results: We found that PD-1 was upregulated and miR-138 was downregulated in patients with CHB, LC, and HCC. Correlations analysis revealed that PD-1 expression was positively correlated with HBV DNA viral load whereas miR-138 was negatively correlated. Luciferase assay results showed that miR-138 directly inhibited PD-1 expression by interacting with the 3'-untranslated region of PD-1. As a result of miR-138 overexpression in primary T cells, PD-1 in these T cells was downregulated and antivirus cytokines secreted by T cells were significantly upregulated. In addition, the expression levels of PD-1 and miR-138 were reversed in patients with CHB who received antivirus treatments. Conclusion: Results showed that miR-138 can promote T-cell responses within patients with HBV infection by inducing a PD-1 blockade. Such an effect suggests that miR-138 may serve as a new therapeutic target for the treatment of HBV infection.

MicroRNA‐155 Regulates Interferon‐γ Production in Natural Killer Cells Via Tim‐3 Signalling in Chronic Hepatitis C Virus Infection

Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B

T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection

T Cell Immunoglobulin- and Mucin-Domain-containing Molecule-3 (Tim-3) Mediates Natural Killer Cell Suppression in Chronic Hepatitis B.

MicroRNAs may solve the mystery of chronic hepatitis B virus infection.

Tim-3 suppression combined with TLR3 activation enhances antiviral immune response in patients with chronic HCV infection

HCV-Induced miR-21 Contributes to Evasion of Host Immune System by Targeting MyD88 and IRAK1

HCV‐induced Mir146a Controls SOCS1/STAT3 and Cytokine Expression in Monocytes to Promote Regulatory T‐cell Development

Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection

Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells

Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Regulate T-Cell Differentiation And Function Via The Signal Transducer And Activator Of Transcription 3 Pathway

Tim‐3 blockade promotes iNKT cell function to inhibit HBV replication

MicroRNA-138 Regulates T-Cell Function by Targeting PD-1 in Patients with Hepatitis B Virus-Related Liver Diseases

TIGIT Signaling Pathway Regulates Natural Killer Cell Function in Chronic Hepatitis B Virus Infection

Blockade of Tim-3 Pathway Ameliorates Interferon-γ Production from Hepatic CD8+ T Cells in a Mouse Model of Hepatitis B Virus Infection

Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection

An HBV-encoded miRNA activates innate immunity to restrict HBV replication

Impaired Toll-Like Receptor 3-Mediated Immune Responses from Macrophages of Patients Chronically Infected with Hepatitis C Virus

Decline of Mir‐124 in Myeloid Cells Promotes Regulatory T‐cell Development in Hepatitis C Virus Infection

HCV‐infected Hepatocytes Drive CD4+CD25+Foxp3+ Regulatory T‐cell Development Through the Tim‐3/Gal‐9 Pathway

MiRNA-548ah, a Potential Molecule Associated with Transition from Immune Tolerance to Immune Activation of Chronic Hepatitis B